LNA-mediated microRNA silencing in non-human primates
The DOI matches its Crossref record; 25 of the 25 references it cites were found in a registry or an index.
Abstract
microRNAs (miRNAs) are small regulatory RNAs that are important in development and disease and therefore represent a potential new class of targets for therapeutic intervention. Despite recent progress in silencing of miRNAs in rodents, the development of effective and safe approaches for sequence-specific antagonism of miRNAs in vivo remains a significant scientific and therapeutic challenge. Moreover, there are no reports of miRNA antagonism in primates. Here we show that the simple systemic delivery of a unconjugated, PBS-formulated locked-nucleic-acid-modified oligonucleotide (LNA-antimiR) effectively antagonizes the liver-expressed miR-122 in non-human primates. Acute administration by intravenous injections of 3 or 10 mg kg(-1) LNA-antimiR to African green monkeys resulted in uptake of the LNA-antimiR in the cytoplasm of primate hepatocytes and formation of stable heteroduplexes between the LNA-antimiR and miR-122. This was accompanied by depletion of mature miR-122 and dose-dependent lowering of plasma cholesterol. Efficient silencing of miR-122 was achieved in primates by three doses of 10 mg kg(-1) LNA-antimiR, leading to a long-lasting and reversible decrease in total plasma cholesterol without any evidence for LNA-associated toxicities or histopathological changes in the study animals. Our findings demonstrate the utility of systemically administered LNA-antimiRs in exploring miRNA function in rodents and primates, and support the potential of these compounds as a…
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Recently, some reports have shown that an anti-microRNA antisense oligonucleotide efficiently blocked the function of the microRNA, thereby alleviating diseases in rodents and nonhuman primates (29,30).”
From ZFP36L1 and ZFP36L2 control LDLR mRNA stability via the ERK–RSK pathway (2014) · cites this paper as [29]
Citations
Cites
Bartel (2004) · doi:10.1016/s0092-8674(04)00045-5 · Cited by 34,714
Bioconductor: open software development for computational biology and bioinformatics
Gentleman, R. C., Carey, V. J., Bates, D. M., Bolstad, B., Dettling, M., Dudoit, S., Ellis, B., Gautier, L., Ge, Y., Gentry, J., et al. (2004) · Genome Biology · doi:10.1186/gb-2004-5-10-r80 · Cited by 12,172
Lewis, B. P., Burge, C. B., & Bartel, D. P. (2005) · Cell · doi:10.1016/j.cell.2004.12.035 · Cited by 11,855
The functions of animal microRNAs
Ambros, V. (2004) · Nature · doi:10.1038/nature02871 · Cited by 10,728
MicroRNA expression profiles classify human cancers
Lu, J., Getz, G., Miska, E. A., Alvarez-Saavedra, E., Lamb, J., Peck, D., Sweet-Cordero, A., Ebert, B. L., Mak, R. H., Ferrando, A. A., et al. (2005) · Nature · doi:10.1038/nature03702 · Cited by 9,539
MicroRNA signatures in human cancers
Calin, G. A., & Croce, C. M. (2006) · Nature Reviews Cancer · doi:10.1038/nrc1997 · Cited by 7,590
Oncomirs—MicroRNAs with a role in cancer
Esquela-Kerscher, A., & Slack, F. J. (2006) · Nature Reviews Cancer · doi:10.1038/nrc1840 · Cited by 5,884
Microarray analysis shows that some microRNAs downregulate large numbers of target mRNAs
Lim, L. P., Lau, N. C., Garrett-Engele, P., Grimson, A., Schelter, J. M., Castle, J., Bartel, D. P., Linsley, P. S., & Johnson, J. M. (2005) · Nature · doi:10.1038/nature03315 · Cited by 4,755
Silencing of microRNAs in vivo with ‘antagomirs’
Krützfeldt, J., Rajewsky, N., Braich, R., Rajeev, K. G., Tuschl, T., Manoharan, M., & Stoffel, M. (2005) · Nature · doi:10.1038/nature04303 · Cited by 3,949
MicroRNA Targeting Specificity in Mammals: Determinants beyond Seed Pairing
Grimson, A., Farh, K. K.-H., Johnston, W. K., Garrett-Engele, P., Lim, L. P., & Bartel, D. P. (2007) · Molecular Cell · doi:10.1016/j.molcel.2007.06.017 · Cited by 3,766
Cited by
Items 301–400 of 1,004
Bui, T. V., & Mendell, J. T. (2010) · Genes & Cancer · doi:10.1177/1947601910377491 · Cited by 135
MicroRNAs, the immune system and rheumatic disease
Tili, E., Michaille, J., Costinean, S., & Croce, C. M. (2008) · Nature Clinical Practice Rheumatology · doi:10.1038/ncprheum0885 · Cited by 143
RNA Therapeutics in Cardiovascular Disease
Lucas, T., Bonauer, A., & Dimmeler, S. (2018) · Circulation Research · doi:10.1161/circresaha.117.311311 · Cited by 156
Elevated circulating microRNA-122 is associated with obesity and insulin resistance in young adults
Wang, R., Hong, J., Cao, Y., Shi, J., Gu, W., Ning, G., Zhang, Y., & Wang, W. (2015) · European Journal of Endocrinology · doi:10.1530/eje-14-0867 · Cited by 149
“In a subsequent study, miR-122 was targeted by antisense inhibitors 329 in African green monkeys, resulting in dose-dependent lowering of plasma cholesterol 330 (26).”
BackgroundMicroRNAs in acute leukemia: from biological players to clinical contributors
Schotte, D., Pieters, R., & den Boer, M. D. (2012) · Leukemia · doi:10.1038/leu.2011.151 · Cited by 139
“87 In addition, intravenous injections with locked nucleic acid-anti-miR-122 formed stable heteroduplexes with liver-specific miR-122 leading to its depletion from liver in non-human primates”
BackgroundEfficiency and Target Derepression of Anti-miR-92a: Results of a First in Human Study
Abplanalp, W. T., Fischer, A., John, D., Zeiher, A. M., Gosgnach, W., Darville, H., Montgomery, R. L., Pestano, L. A., Allée, G., Paty, I., et al. (2020) · Nucleic Acid Therapeutics · doi:10.1089/nat.2020.0871 · Cited by 164
“For example, miravirsen was reported to have a half-maximal dose of 10 mg/kg in mice and about 3 mg/kg in non-human primates [29].”
MicroRNA Involvement in Signaling Pathways During Viral Infection
Barbu, M. G., Condrat, C. E., Thompson, D. C., Bugnar, O. L., Crețoiu, D., Toader, O. D., Suciu, N., & Voinea, S. C. (2020) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2020.00143 · Cited by 156
Non-coding RNAs in endometriosis: a narrative review
Panir, K., Schjenken, J. E., Robertson, S. A., & Hull, M. L. (2018) · Human Reproduction Update · doi:10.1093/humupd/dmy014 · Cited by 152
Madrigal-Matute, J., Rotllan, N., Aranda, J. F., & Fernández-Hernando, C. (2013) · Current Atherosclerosis Reports · doi:10.1007/s11883-013-0322-z · Cited by 140
Yokobori, T., Suzuki, S., Tanaka, N., Inose, T., Sohda, M., Sano, A., Sakai, M., Nakajima, M., Miyazaki, T., Kato, H., et al. (2013) · Cancer Science · doi:10.1111/cas.12030 · Cited by 138
O’Connor, R. M., Dinan, T. G., & Cryan, J. F. (2011) · Molecular Psychiatry · doi:10.1038/mp.2011.162 · Cited by 146
microRNA regulation of expression of the cystic fibrosis transmembrane conductance regulator gene
Gillen, A. E., Gosalia, N., Leir, S., & Harris, A. (2011) · Biochemical Journal · doi:10.1042/bj20110672 · Cited by 150
Mir-144 selectively regulates embryonic α-hemoglobin synthesis during primitive erythropoiesis
Fu, Y.-F., Du, T.-T., Dong, M., Zhu, K.-Y., Jing, C.-B., Zhang, Y., Wang, L., Fan, H.-B., Chen, Y., Jin, Y., et al. (2009) · Blood · doi:10.1182/blood-2008-08-174854 · Cited by 133
MicroRNAs and atrial fibrillation: mechanisms and translational potential
Luo, X., Yang, B., & Nattel, S. (2014) · Nature Reviews Cardiology · doi:10.1038/nrcardio.2014.178 · Cited by 151
Benatti, R. O., Melo, A. M., Borges, F. O., Ignacio-Souza, L. M., Simino, L. A. P., Milanski, M., Velloso, L. A., Torsoni, M. A., & Torsoni, A. S. (2014) · British Journal of Nutrition · doi:10.1017/s0007114514000579 · Cited by 145
“Others have shown that suppression of miR-122 in non-human primates reduces plasma cholesterol((58,59)).”
BackgroundSilencing of the miR-17∼92 Cluster Family Inhibits Medulloblastoma Progression
Murphy, B. L., Obad, S., Bihannic, L., Ayrault, O., Zindy, F., Kauppinen, S., & Roussel, M. F. (2013) · Cancer Research · doi:10.1158/0008-5472.can-13-0927 · Cited by 136
Self-citationTaipaleenmäki, H., Hokland, L. B., Chen, L., Kauppinen, S., & Kassem, M. S. (2011) · European Journal of Endocrinology · doi:10.1530/eje-11-0646 · Cited by 139
Self-citationmiRNAS in normal and diseased skeletal muscle
Eisenberg, I., Alexander, M. S., & Kunkel, L. M. (2009) · Journal of Cellular and Molecular Medicine · doi:10.1111/j.1582-4934.2008.00524.x · Cited by 133
SREBP: a novel therapeutic target
Xu, X., & Song, B. (2013) · Acta Biochimica et Biophysica Sinica · doi:10.1093/abbs/gms112 · Cited by 154
MicroRNAs: Emerging roles in adipogenesis and obesity
Peng, Y., Yu, S., Li, H., Xiang, H., Peng, J., & Jiang, S. (2014) · Cellular Signalling · doi:10.1016/j.cellsig.2014.05.006 · Cited by 148
Review: The role of microRNAs in kidney disease
Li, J. Y. Z., Yong, T. Y., Michael, M., & Gleadle, J. (2010) · Nephrology · doi:10.1111/j.1440-1797.2010.01363.x · Cited by 150
“While many miRNAs are located within introns of host genes, their expression does not always correlate perfectly with that of host genes suggesting further, posttranscriptional, regulation.(23,111,112) Examples of such regulation are the influence of Lin28 proteins on Let-7 production and p53 on the processing of seve…”
BackgroundMethodmiRNAs and long noncoding RNAs as biomarkers in human diseases
Van Roosbroeck, K., Pollet, J., & Calin, G. A. (2013) · Expert Review of Molecular Diagnostics · doi:10.1586/erm.12.134 · Cited by 134
MicroRNA: Dynamic Regulators of Macrophage Polarization and Plasticity
Self-Fordham, J. B., Naqvi, A. R., Uttamani, J. R., Kulkarni, V., & Nares, S. (2017) · Frontiers in Immunology · doi:10.3389/fimmu.2017.01062 · Cited by 140
MicroRNAs in Metabolism and Metabolic Diseases
Rottiers, V., Najafi-Shoushtari, S. H., Kristo, F., Gurumurthy, S., Zhong, L., Li, Y., Cohen, D. E., Gerszten, R. E., Bardeesy, N., Mostoslavsky, R., et al. (2011) · Cold Spring Harbor Symposia on Quantitative Biology · doi:10.1101/sqb.2011.76.011049 · Cited by 124
Potential Diagnostic, Prognostic and Therapeutic Targets of MicroRNAs in Human Gastric Cancer
Tsai, M.-M., Wang, C., Tsai, C., Huang, H., Chi, H., Lin, Y.-H., Lu, P.-H., & Lin, K. (2016) · International Journal of Molecular Sciences · doi:10.3390/ijms17060945 · Cited by 142
Wang, G., Yao, J., Li, Z., Zu, G., Feng, D., Shan, W., Li, Y., Hu, Y., Zhao, Y., & Tian, X. (2016) · Antioxidants and Redox Signaling · doi:10.1089/ars.2015.6492 · Cited by 137
“The efficacy and safety of LNA-modified nucleotides have been confirmed in murine and nonhuman primate models (19, 18).”
miR-7 and miR-153 protect neurons against MPP+-induced cell death via upregulation of mTOR pathway
Fragkouli, A., & Doxakis, E. (2014) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2014.00182 · Cited by 147
MicroRNAs: potential mediators and biomarkers of diabetic complications
Kato, M. V., Castro, N., & Natarajan, R. D. (2013) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2013.06.009 · Cited by 137
“For instance, locked nucleic acid (LNA) and modified anti-miRNAs (antimiRs or antagomirs) have been shown to be highly specific in inhibiting the miRNA of interest and are also being tested in clinical trials [75,149,150].”
The emerging role of microRNAs in multiple sclerosis
Junker, A., Hohlfeld, R., & Meinl, E. (2011) · Nature Reviews Neurology · doi:10.1038/nrneurol.2010.179 · Cited by 129
Editorial focus: understanding off-target effects as the key to successful RNAi therapy
Bartoszewski, R., & Sikorski, A. F. (2019) · Cellular & Molecular Biology Letters · doi:10.1186/s11658-019-0196-3 · Cited by 147
Sedano, C., & Sarnow, P. (2014) · Cell Host and Microbe · doi:10.1016/j.chom.2014.07.006 · Cited by 128
“Modified locked nucleic acids (LNAs) with base complementarity to miR-122 or control miR-106b (Elmen et al., 2008; Machlin et al., 2012) were transfected one day after infection with HCV.”
MethodSelf-citationMicroRNA regulation of cardiac conduction and arrhythmias
Kim, G. H. (2012) · Translational research · doi:10.1016/j.trsl.2012.12.004 · Cited by 140
“Single-stranded oligonucleotides have been shown to be effective in inactivating miRNAs in vivo (16, 17).”
BackgroundExperimental identification of microRNA-140 targets by silencing and overexpressing miR-140
Nicolás, F. E., Pais, H., Schwach, F., Lindow, M., Kauppinen, S., Moulton, V., & Dalmay, T. (2008) · RNA · doi:10.1261/rna.1221108 · Cited by 124
“Translation of mRNAs targeted by miRNAs is repressed and the steady-state level of some but not all mRNA targets is also reduced (Wightman et al. 1993; Bagga et al. 2005; Pillai et al. 2005; Petersen et al. 2006; Parker and Sheth 2007; Eulalio et al. 2008).”
Self-citationHighly Complementary Target RNAs Promote Release of Guide RNAs from Human Argonaute2
De, N., Young, L., Lau, P.-W., Meisner, N.-C., Morrissey, D. V., & MacRae, I. J. (2013) · Molecular Cell · doi:10.1016/j.molcel.2013.04.001 · Cited by 128
“…can act as competitive inhibitors of miRNA function, i.e., by sequestering a miRNA, but not changing its cellular concentration (Davis et al., 2009; Elmén et al., 2008; Torres et al., 2011), or by promoting miRNA degradation (Esau et al., 2006; Krützfeldt et al., 2005; Torres et al., 2011).”
The Therapeutic Potential of MicroRNAs in Cancer
Thorsen, S. B., Obad, S., Jensen, N. F., Stenvang, J., & Kauppinen, S. (2012) · The Cancer Journal · doi:10.1097/ppo.0b013e318258b5d6 · Cited by 126
“In this study, systemic delivery of unconjugated, saline-formulated antimiR-122 resulted in efficient sequestration of miR-122, leading to dose-dependent and longlasting decrease in serum cholesterol levels in African green monkeys without any evidence of acute or subchronic toxicities in the study animals.(70) More r…”
BackgroundMethodInfluentialSelf-citationEpigenetic changes in patients with multiple sclerosis
Koch, M. W., Metz, L. M., & Kovalchuk, O. (2012) · Nature Reviews Neurology · doi:10.1038/nrneurol.2012.226 · Cited by 158
Tissue engineering strategies for the induction of angiogenesis using biomaterials
Saberianpour, S., Heidarzadeh, M., Geranmayeh, M. H., Hosseinkhani, H., Rahbarghazi, R., & Nouri, M. (2018) · Journal of Biological Engineering · doi:10.1186/s13036-018-0133-4 · Cited by 167
General rules for functional microRNA targeting
Kim, D., Sung, Y. M., Park, J., Kim, S., Kim, J., Park, J., Ha, H., Bae, J. Y., Kim, S., & Baek, D. (2016) · Nature Genetics · doi:10.1038/ng.3694 · Cited by 138
MicroRNAs in cancer biology and therapy: Current status and perspectives
Price, C., & Chen, J. (2014) · Genes & Diseases · doi:10.1016/j.gendis.2014.06.004 · Cited by 137
Jimenez-Mateos, E. M., & Henshall, D. C. (2013) · Neuroscience · doi:10.1016/j.neuroscience.2013.02.027 · Cited by 125
Liver microRNAs: potential mediators and biomarkers for metabolic and cardiovascular disease?
Willeit, P., Skroblin, P., Kiechl, S. J., Fernandez-Hernando, C. F., & Mayr, M. (2016) · European Heart Journal · doi:10.1093/eurheartj/ehw146 · Cited by 134
Hromadníková, I., Kotlabová, K., Hympanova, L. H., & Krofta, L. (2015) · PLoS ONE · doi:10.1371/journal.pone.0138383 · Cited by 131
Liu, N., Jiang, N., Guo, R., Jiang, W., He, Q.-M., Xu, Y.-F., Li, Y.-Q., Tang, L., Mao, Y., Sun, Y. H., et al. (2013) · Molecular Cancer · doi:10.1186/1476-4598-12-123 · Cited by 121
“Inhibiting or reconstituting special miRNA may have therapeutic implication and makes them candidates for therapeutic targets [13-16].”
BackgroundThe Emerging Role of microRNAs and Nutrition in Modulating Health and Disease
Ross, S. A., & Davis, C. D. (2014) · Annual Review of Nutrition · doi:10.1146/annurev-nutr-071813-105729 · Cited by 127
MicroRNAs, diet, and cancer: New mechanistic insights on the epigenetic actions of phytochemicals
Parasramka, M. A., Ho, E., Williams, D. E., & Dashwood, R. H. (2011) · Molecular Carcinogenesis · doi:10.1002/mc.20822 · Cited by 122
“secured by a methylene bridge connecting the 20-O atom and the 40-C atom, leading to successful knockdown of specific miRNAs [185,186].”
BackgroundLocked nucleic acid as a novel class of therapeutic agents
Veedu, R. N., & Wengel, J. (2009) · RNA Biology · doi:10.4161/rna.6.3.8807 · Cited by 124
Development of mi RNA ‐based therapeutic approaches for cancer patients
Takahashi, R., Prieto‐Vila, M., Kohama, I., & Ochiya, T. (2019) · Cancer Science · doi:10.1111/cas.13965 · Cited by 140
Review: The Role of MicroRNAs in Osteoarthritis and Chondrogenesis
Le, L. T. T., Swingler, T. E., & Clark, I. M. (2013) · Arthritis & Rheumatism · doi:10.1002/art.37990 · Cited by 125
An overview of the clinical application of antisense oligonucleotides for RNA-targeting therapies
McClorey, G., & Wood, M. J. A. (2015) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2015.07.005 · Cited by 142
Fukuhara, T., Kambara, H., Shiokawa, M., Ono, C., Katoh, H., Morita, E., Okuzaki, D., Maehara, Y., Koike, K., & Matsuura, Y. (2012) · Journal of Virology · doi:10.1128/jvi.00567-12 · Cited by 121
Regulation of miR-19 to Breast Cancer Chemoresistance Through Targeting PTEN
Liang, Z., Li, Y., Huang, K., Wagar, N., & Shim, H. (2011) · Pharmaceutical Research · doi:10.1007/s11095-011-0570-y · Cited by 124
Yin, C., Wang, X., & Kukreja, R. C. (2008) · FEBS Letters · doi:10.1016/j.febslet.2008.11.014 · Cited by 115
“antagonized the liver-expressed miRNA-122 [39].”
MicroRNAs in Cancer: A Historical Perspective on the Path from Discovery to Therapy
Orellana, E. A., & Kasinski, A. L. (2015) · Cancers · doi:10.3390/cancers7030842 · Cited by 128
“The authors showed that the LNA-antagomiR was able to antagonize miR-122 efficiently and in a dose dependent manner, leading to decreased levels of cholesterol in plasma [78].”
BackgroundMethodInfluentialRegulation of IGF -1 signaling by microRNAs
Jung, H. J., & Suh, Y. (2015) · Frontiers in Genetics · doi:10.3389/fgene.2014.00472 · Cited by 117
Iron-Responsive miR-485-3p Regulates Cellular Iron Homeostasis by Targeting Ferroportin
Sangokoya, C., Doss, J. F., & Chi, J.-T. (2013) · PLoS Genetics · doi:10.1371/journal.pgen.1003408 · Cited by 124
“Therapeutic inhibition of miR-122 with locked nucleic acid–modified oligonucleotides [51] has recently been shown to successfully lower hepatitis C virus (HCV) replication in chronically infected primate models and lead to long-lasting suppression of HCV viremia and improvement of HCV-induced liver pathology [52].”
BackgroundDeregulation of microRNA expression in thyroid neoplasias
Pallante, P., Battista, S., Pierantoni, G. M., & Fusco, A. (2013) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2013.223 · Cited by 128
Pathogenic arterial remodeling: the good and bad of microRNAs
Wei, Y., Schober, A., & Weber, C. (2013) · American Journal of Physiology-Heart and Circulatory Physiology · doi:10.1152/ajpheart.00267.2012 · Cited by 125
MicroRNA in central nervous system trauma and degenerative disorders
Liu, N.-K., & Xu, X.-M. (2011) · Physiological Genomics · doi:10.1152/physiolgenomics.00168.2010 · Cited by 109
“Brain ischemia 8 miRNAs1 and 12 miRNAs2 at 3 h and 3 days; decreased miR-145 resulted in increased translation of its mRNA target, superoxide dismutase-2; in silico analysis showed sequence complementarity of 8 miRNAs induced after focal ischemia to 877 promoters several target proteins known to mediate inflammation,…”
microRNA expression in the eyes and their significance in relation to functions
Xu, S. (2008) · Progress in Retinal and Eye Research · doi:10.1016/j.preteyeres.2008.11.003 · Cited by 115
Shibata, C., Ohno, M., Otsuka, M., Kishikawa, T., Goto, K., Muroyama, R., Kato, N., Yoshikawa, T., Takata, A., & Koike, K. (2014) · Virology · doi:10.1016/j.virol.2014.05.024 · Cited by 116
Manfé, V., Biskup, E., Rosbjerg, A., Kamstrup, M. R., Skov, A. G., Lerche, C. M., Lauenborg, B. T., Ødum, N., & Gniadecki, R. (2012) · PLoS ONE · doi:10.1371/journal.pone.0029541 · Cited by 117
“primates (Miravirsen, Santaris Pharma A/S) [49–51].”
MicroRNA-based therapeutics in cardiovascular disease: screening and delivery to the target
Mellis, D. J., & Caporali, A. (2017) · Biochemical Society Transactions · doi:10.1042/bst20170037 · Cited by 147
The clinical potential of microRNAs
Budhu, A., Ji, J., & Wang, X. W. (2010) · Journal of Hematology & Oncology · doi:10.1186/1756-8722-3-37 · Cited by 109
“Inhibition of mature microRNA LNA-antagomiR Unconjugated Silence OncomiR [ 99 ]”
BackgroundNon-coding RNAs: a key to future personalized molecular therapy?
Galasso, M., Elena Sana, M., & Volinia, S. (2010) · Genome Medicine · doi:10.1186/gm133 · Cited by 108
“Acute administration by intravenous injections of 3 or 10 mg/kg LNA-AMO to African green monkeys resulted in uptake of the LNA-AMO in the cytoplasm of primate hepatocytes and formation of stable heteroduplexes between the LNA-AMO and miR-122 [ 63 ].”
BackgroundMicroRNA-mediated control in the skin
Yi, R., & Fuchs, E. (2010) · Cell Death & Differentiation · doi:10.1038/cdd.2009.92 · Cited by 111
The role of microRNAs in metastasis and epithelial-mesenchymal transition
Bracken, C. P., Gregory, P. A., Khew‐Goodall, Y., & Goodall, G. J. (2009) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-009-8750-1 · Cited by 128
Zeisel, M., Lupberger, J., Fofana, I., & Baumert, T. (2013) · Journal of Hepatology · doi:10.1016/j.jhep.2012.09.022 · Cited by 114
“Given the physiological role of miR122 in cholesterol metabolism, miravirsen/SPC3649 led to markedly lowered serum cholesterol in animals but no important adverse effects were observed [61-63].”
BackgroundEfficient in vivo microRNA targeting of liver metastasis
Huynh, C., Segura, M., Gaziel-Sovran, A., Menéndez, S., Darvishian, F., Chiriboga, L., Levin, B., Meruelo, D., Osman, I., Zavadil, J., et al. (2011) · Oncogene · doi:10.1038/onc.2010.523 · Cited by 114
“, 2006) into mice, rats and nonhuman primates (Elmen et al., 2008).”
BackgroundRole of miRNAs in the progression of malignant melanoma
Mueller, D. W., & Bosserhoff, A. (2009) · British Journal of Cancer · doi:10.1038/sj.bjc.6605204 · Cited by 120
“Actually, Elmen et al (2008) successfully antagonised the expression of the liver-specific miRNA, miR-122, in African green monkeys by a simple systemic delivery of unconjugated, PBS-formulated LNA-antimiRs.”
BackgroundRNA Mediated toll-like receptor stimulation in health and disease
Dalpke, A. H., & Helm, M. (2012) · RNA Biology · doi:10.4161/rna.20206 · Cited by 113
MicroRNAs in vascular aging and atherosclerosis
Menghini, R., Stöhr, R., & Federici, M. (2014) · Ageing Research Reviews · doi:10.1016/j.arr.2014.03.005 · Cited by 125
Noncoding RNAs: key molecules in understanding and treating pain
Bali, K. K., & Kuner, R. (2014) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2014.05.006 · Cited by 114
MicroRNAs as therapeutic targets in human cancers
Shah, M., & Călin, G. A. (2014) · Wiley Interdisciplinary Reviews - RNA · doi:10.1002/wrna.1229 · Cited by 124
Noncoding RNA s and immune checkpoints—clinical implications as cancer therapeutics
Smolle, M. A., Calin, H. N., Pichler, M., & Calin, G. A. (2017) · The FEBS Journal · doi:10.1111/febs.14030 · Cited by 113
Murata, K., Ito, H., Yoshitomi, H., Yamamoto, K., Fukuda, A., Yoshikawa, J., Moritoshi, F., Ishikawa, M., Shibuya, H., & Matsuda, S. (2013) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.2040 · Cited by 119
miRNA cassettes in viral vectors: Problems and solutions
Liu, Y. P., & Berkhout, B. (2011) · Biochimica et Biophysica Acta (BBA) - Gene Regulatory Mechanisms · doi:10.1016/j.bbagrm.2011.05.014 · Cited by 109
“Consistently, another group showed that miR-122 silencing using locked nucleic acid modified oligonucleotides (LNA-antimiR) led to a long-lasting decrease in serum cholesterol in mice and African monkeys [247].”
BackgroundRNAi-based therapeutic strategies for metabolic disease
Czech, M., Aouadi, M., & Tesz, G. J. (2011) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2011.57 · Cited by 118
An Introduction to Small Non-coding RNAs: miRNA and snoRNA
Holley, C. L., & Topkara, V. K. (2011) · Cardiovascular Drugs and Therapy · doi:10.1007/s10557-011-6290-z · Cited by 125
“Subsequent publications have shown similar success in non-human primates [55], as well as in models of cardiac hypertrophy [54] and breast cancer [56], Several companies have already been formed with the goal of developing novel therapeutics targeting miRNA, including Regulus Therapeutics, miRagen, and Mirna Therapeut…”
BackgroundDeregulation of microRNA expression in follicular cell-derived human thyroid carcinomas
Pallante, P., Visone, R., Croce, C. M., & Fusco, A. (2009) · Endocrine Related Cancer · doi:10.1677/erc-09-0217 · Cited by 111
Gene Therapy for the Heart Lessons Learned and Future Perspectives
Cannata, A. N., Ali, H., Sinagra, G., & Giacca, M. (2020) · Circulation Research · doi:10.1161/circresaha.120.315855 · Cited by 161
Micromanaging Vascular Biology: Tiny MicroRNAs Play Big Band
Sen, C. K., Gordillo, G. M., Khanna, S., & Roy, S. (2009) · Journal of Vascular Research · doi:10.1159/000226221 · Cited by 97
“These include 2′- O -methyl-group (OMe)-modified oligonucleotides, 2′- O -methoxyethyl (MOE)-modified oligonucleotides, which have higher affinity and specificity to RNA than their OMe-analogs, and locked nucleic acid (LNA)-modified oligonucleotides (LNA-antimiR), in which the 2′- O -oxygen is bridged to the 4′-positi…”
BackgroundPCSK9 as a therapeutic target of dyslipidemia
Seidah, N. G. (2009) · Expert Opinion on Therapeutic Targets · doi:10.1517/14728220802600715 · Cited by 110
“LNA injection twice weekly results in a neutralizing effect that can last for up to 21 days [71,72] .”
BackgroundThe promise of microRNA-based therapies in Alzheimer’s disease: challenges and perspectives
Walgrave, H., Zhou, L., De Strooper, B., & Salta, E. (2021) · Molecular Neurodegeneration · doi:10.1186/s13024-021-00496-7 · Cited by 131
Vinall, R., Ripoll, A., Wang, S., Pan, C., & White, R. D. D. (2011) · International Journal of Cancer · doi:10.1002/ijc.26256 · Cited by 110
Torres, A. G., Fabani, M. M., Vigorito, E., Williams, D., Al-Obaidi, N., Wojciechowski, F., Hudson, R. H. E., Seitz, O., & Gait, M. J. (2011) · Nucleic Acids Research · doi:10.1093/nar/gkr885 · Cited by 123
“Inhibition of miR-122 has been shown to lead to lowering of plasma cholesterol levels in mice and primates (18,19,21).”
BackgroundInfluentialNagata, Y., Nakasa, T., Mochizuki, Y., Ishikawa, M., Miyaki, S., Shibuya, H., Yamasaki, K., Adachi, N., Asahara, H., & Ochi, M. (2009) · Arthritis & Rheumatism · doi:10.1002/art.24762 · Cited by 115
ZFP36L1 and ZFP36L2 control LDLR mRNA stability via the ERK–RSK pathway
Adachi, S., Homoto, M., Tanaka, R., Hioki, Y., Murakami, H., Suga, H., Matsumoto, M., Nakayama, K. I., Hatta, T., Iemura, S.-I., et al. (2014) · Nucleic Acids Research · doi:10.1093/nar/gku652 · Cited by 109
“Recently, some reports have shown that an anti-microRNA antisense oligonucleotide efficiently blocked the function of the microRNA, thereby alleviating diseases in rodents and nonhuman primates (29,30).”
BackgroundMicroRNAs as Potential Biomarkers in Atherosclerosis
Churov, A. V., Summerhill, V. I., Grechko, A. V., Orekhova, V. A., & Orekhov, A. N. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20225547 · Cited by 130
“Similar results were presented by another study that also used non-human primates [127].”
BackgroundResultA New Level of Complexity: The Role of MicroRNAs in Cardiovascular Development
Boettger, T., & Braun, T. W. (2012) · Circulation Research · doi:10.1161/circresaha.111.247742 · Cited by 121
Breast cancer and microRNAs: therapeutic impact
Iorio, M. V., Casalini, P., Piovan, C., Braccioli, L., & Tagliabue, E. (2011) · The Breast · doi:10.1016/s0960-9776(11)70297-1 · Cited by 122
Jun, S., Datta, S., Wang, L., Pegany, R. B., Cano, M., & Handa, J. T. (2018) · Experimental Eye Research · doi:10.1016/j.exer.2018.09.023 · Cited by 127
Dhir, A., Dhir, S., Proudfoot, N. J., & Jopling, C. L. (2015) · Nature Structural & Molecular Biology · doi:10.1038/nsmb.2982 · Cited by 146
miRNA-Based Therapeutic Strategies
Ishida, M., & Selaru, F. M. (2012) · Current Pathobiology Reports · doi:10.1007/s40139-012-0004-5 · Cited by 134
“In vivo antisense blockade of miRNA-122 in liver results in significantly decreased plasma cholesterol levels in mice, as well as in non-human primates [29, 35].”
A Locked Nucleic Acid Oligonucleotide Targeting MicroRNA 122 Is Well-Tolerated in Cynomolgus Monkeys
Hildebrandt-Eriksen, E. S., Aarup, V., Persson, R., Hansen, H. F., Munk, M. E., & ørum, H. (2012) · Nucleic Acid Therapeutics · doi:10.1089/nat.2011.0332 · Cited by 96
“The miR-122 antagonist miravirsen is an oligonucleotide containing LNA residues (Elmen et al., 2008a).”
InfluentialSelf-citationTargeting microRNAs in obesity
Xie, H., Sun, L., & Lodish, H. F. (2009) · Expert Opinion on Therapeutic Targets · doi:10.1517/14728220903190707 · Cited by 122
“[83] used unconjugated LNAs to antagonize miR-122 in non-human primates.”
Kotani, A., Ha, D., Hsieh, J. J.-D., Rao, P. K., Schotte, D., den Boer, M. L., Armstrong, S. A., & Lodish, H. F. (2009) · Blood · doi:10.1182/blood-2008-12-191619 · Cited by 108
Vandghanooni, S., Eskandani, M., Barar, J., & Omidi, Y. (2018) · Nanomedicine · doi:10.2217/nnm-2018-0205 · Cited by 110
MicroRNAs as pharmacological targets in endothelial cell function and dysfunction
Chamorro-Jorganes, A., Araldi, E., & Suárez, Y. (2013) · Pharmacological Research · doi:10.1016/j.phrs.2013.04.002 · Cited by 122
Xiao, L., Wu, J., Wang, J.-Y., Chung, H., Kalakonda, S., Rao, J., Gorospe, M., & Wang, J.-Y. (2017) · Gastroenterology · doi:10.1053/j.gastro.2017.10.009 · Cited by 106
Non-cardiomyocyte microRNAs in heart failure
Tijsen, A. J., Pinto, Y. M., & Creemers, E. E. (2012) · Cardiovascular Research · doi:10.1093/cvr/cvr344 · Cited by 89
“On the other hand, antimiRs seem to inhibit miRNA activity by the formation of a very stable complex with the mature miRNA, visualized by a slower migrating complex on northern blot assays.(20,21) Secondly, despite effective binding of the miRNA by both antagomirs and antimiRs, the LNA-modified antimiRs have been show…”
Background
Metadata
- Authors
- Elmén, J., Lindow, M., Schütz, S., Lawrence, M., Petri, A., Obad, S., Lindholm, M., Hedtjärn, M., Hansen, H. F., Berger, U., Gullans, S., Kearney, P., Sarnow, P., Straarup, E. M., & Kauppinen, S.
- Affiliations
- Stanford Medicine (US)
- University of Copenhagen (DK)
- Corresponding author
- Kauppinen, Sakari
- Venue
- Nature
- Published
- 2008-03-26
- Volume
- 452
- Issue
- 7189
- Pages
- 896-899
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- OpenAlex
- W2142310248
- Cited by
- 1,589
- References
- 0
- Citations by year
- 2026: 13 · 2025: 20 · 2024: 23 · 2023: 23 · 2022: 54 · 2021: 48 · 2020: 63 · 2019: 66 · 2018: 62 · 2017: 75 · 2016: 100 · 2015: 113 · 2014: 139 · 2013: 176 · 2012: 175
- FWCI
- 60.00
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature (publishedVersion)
- PubMed (publishedVersion)
- Research at the University of Copenhagen (University of Copenhagen) (publishedVersion)
- RePEc: Research Papers in Economics (submittedVersion)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA Interference and Gene Delivery
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › MicroRNA in disease regulation
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Biochemistry › Cholesterol and Lipid Metabolism
- Keywords
- microRNA silencing, locked nucleic acid, miR-122, cholesterol lowering, vervet monkey, non-human primates, hepatocyte uptake, heteroduplex formation, serum cholesterol, siRNA, oligonucleotide toxicity, gene expression regulation, drug target validation
- MeSH terms
- Animals, Chlorocebus aethiops, Female, Mice, Inbred C57BL, Oligonucleotides, Gene Silencing, MicroRNAs, Mice
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.